Credo Technology Group enters the post-earnings session with a sharp reset: the stock fell 8.6% on September 1, extending a near-identical weekly decline, as fiscal Q1 results landed and the Street immediately moved to revise its numbers lower.
The analyst response tells the clearest story. Multiple firms cut price targets on the same day, all while holding their positive ratings — the hallmark of a "good company, expensive stock" recalibration rather than a change in conviction. JP Morgan's Joseph Cardoso trimmed to $310 from $335, keeping Overweight. BofA's Vivek Arya dropped to $275 from $340, staying at Buy. Evercore ISI cut to $292 from $325, maintaining Outperform. Only Rosenblatt moved against the tide, nudging its Neutral target up to $235 from $215 — a level that sits just above the current price of $206.63. The consensus mean target is now $277.81, implying roughly 34% upside from here, but that figure will migrate lower as more teams update. The previous note flagged the valuation premium going into results; the Street has now partially acknowledged it without abandoning the bull thesis.
The short interest picture has shifted modestly since the earnings preview published September 1. Shorts added roughly 9.5% on a weekly basis through the run-up, pushing SI to 3.56% of the free float. The September 1 print shows a marginal 0.1% single-day retreat, consistent with some short-covering immediately after the announcement. That level — just over 6 million shares — remains unexceptional in absolute terms. Borrow costs have eased sharply too, dropping 33% on the week to just 0.31%, and availability is effectively uncapped, with far more shares available to borrow than there are shorts in the market. There is no squeeze pressure here, and no sign the lending market is tightening in response to the move.
Options positioning is similarly muted. The put/call ratio of 0.91 is fractionally below its 20-day average of 0.92, a z-score of -0.33. That is essentially neutral — options traders are not piling into protection after the selloff, nor are they aggressively buying calls on the dip. The 52-week PCR range runs from 0.675 to 1.36, so the current reading sits in the lower half of the distribution, closer to complacency than defensiveness. The days-to-cover of 1.43 (from the most recent FINRA fortnightly) confirms that short interest is not material enough to create a meaningful overhang.
Institutional and insider activity adds limited colour. T. Rowe Price added over 2.2 million shares through July, the most aggressive accumulation among the top holders. BlackRock remains the largest institutional name with 9.5% of shares, though the most recent 13G/A filed in late July showed a reduction from 9.0% to 7.7% as-last-disclosed — worth noting given the disclosure caveat that stakes are as-filed and holders dropping below 5% may not file again. On the insider side, COO Yat Tung Lam sold approximately $13 million of stock on July 31 across multiple tranches, all under a pre-arranged 10b5-1 plan. Planned sales carry less informational weight than discretionary ones, but the scale is notable. The CEO's one trade in the dataset carries a date of November 2027, which appears to be a data artefact and has been excluded.
The fundamental debate remains intact but has been repriced. Bulls lean on Credo's positioning in high-speed data-centre connectivity and the optical portfolio that management and analysts see driving an inflection in the second half of fiscal 2027. The bear case is essentially a timing argument: slower first-half growth, customer concentration risk, and a valuation — PE near 30x trailing, PB above 10x — that leaves little room for execution misses. The ORTEX short score of 31.7 has been flat over the past two weeks, suggesting no dramatic change in the composite short-selling signal despite the price action. The days-to-cover factor ranks in the 97th percentile, reflecting how lightly shorted the name is relative to its trading volume — a structural feature, not a near-term catalyst.
What to watch next: the next scheduled earnings event is October 12, and the key question between now and then is whether the analyst target reductions stabilise or accelerate as more teams digest the Q1 print and management's second-half ramp guidance.
See the live data behind this article on ORTEX.
Open CRDO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
